AID Genomics
Rehovot, Israel· Est.
Precision genomic diagnostics for oncology, rare disease and infectious disease, delivered at affordable scale.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $20M
AI Company Overview
Precision genomic diagnostics for oncology, rare disease and infectious disease, delivered at affordable scale.
OncologyRare Genetic DiseasesInfectious Diseases
Technology Platform
Hybrid NGS, miRNA, epigenetic sequencing combined with AI‑driven bio‑informatics for liquid‑biopsy and tissue‑based diagnostics.
Opportunities
Expansion into global liquid‑biopsy markets and emerging economies, leveraging AI‑driven analytics to offer cost‑effective companion diagnostics for targeted therapies.
Risk Factors
Regulatory approval and reimbursement hurdles across jurisdictions, and competition from larger NGS and diagnostics firms with deeper capital resources.
Competitive Landscape
Competes with Guardant Health, Illumina, Roche and other liquid‑biopsy providers; differentiation lies in integrated AI analytics, low‑cost pricing and a focus on both oncology and rare‑disease testing.